455 related articles for article (PubMed ID: 22373734)
1. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs.
Hayashi S; Ueno N; Murase A; Takada J
J Enzyme Inhib Med Chem; 2014 Dec; 29(6):846-67. PubMed ID: 24517373
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
Imanishi J; Morita Y; Yoshimi E; Kuroda K; Masunaga T; Yamagami K; Kuno M; Hamachi E; Aoki S; Takahashi F; Nakamura K; Miyata S; Ohkubo Y; Mutoh S
Biochem Pharmacol; 2011 Oct; 82(7):746-54. PubMed ID: 21745460
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.
Biava M; Porretta GC; Poce G; Supino S; Forli S; Rovini M; Cappelli A; Manetti F; Botta M; Sautebin L; Rossi A; Pergola C; Ghelardini C; Vivoli E; Makovec F; Anzellotti P; Patrignani P; Anzini M
J Med Chem; 2007 Nov; 50(22):5403-11. PubMed ID: 17915854
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity.
Ndengele MM; Cuzzocrea S; Esposito E; Mazzon E; Di Paola R; Matuschak GM; Salvemini D
FASEB J; 2008 Sep; 22(9):3154-64. PubMed ID: 18497304
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; ElTahir KE
Bioorg Med Chem; 2012 May; 20(10):3306-16. PubMed ID: 22516672
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biologic evaluation of substituted 5-methyl-2-phenyl-1H-pyrazol-3(2H)-one derivatives as selective COX-2 inhibitors: molecular docking study.
Dube PN; Bule SS; Mokale SN; Kumbhare MR; Dighe PR; Ushir YV
Chem Biol Drug Des; 2014 Oct; 84(4):409-19. PubMed ID: 24636540
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of glycolamide esters of indomethacin as potential cyclooxygenase-2 (COX-2) inhibitors.
Khanna S; Madan M; Vangoori A; Banerjee R; Thaimattam R; Jafar Sadik Basha SK; Ramesh M; Casturi SR; Pal M
Bioorg Med Chem; 2006 Jul; 14(14):4820-33. PubMed ID: 16581252
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.
Anzini M; Rovini M; Cappelli A; Vomero S; Manetti F; Botta M; Sautebin L; Rossi A; Pergola C; Ghelardini C; Norcini M; Giordani A; Makovec F; Anzellotti P; Patrignani P; Biava M
J Med Chem; 2008 Aug; 51(15):4476-81. PubMed ID: 18598017
[TBL] [Abstract][Full Text] [Related]
15. Aspirin analogues as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, nitric oxide release, molecular modeling, and biological evaluation as anti-inflammatory agents.
Kaur J; Bhardwaj A; Huang Z; Knaus EE
ChemMedChem; 2012 Jan; 7(1):144-50. PubMed ID: 22095955
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Abdel-Aziz AA; ElTahir KE; Asiri YA
Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
[TBL] [Abstract][Full Text] [Related]
17. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Harris RR; Black L; Surapaneni S; Kolasa T; Majest S; Namovic MT; Grayson G; Komater V; Wilcox D; King L; Marsh K; Jarvis MF; Nuss M; Nellans H; Pruesser L; Reinhart GA; Cox B; Jacobson P; Stewart A; Coghlan M; Carter G; Bell RL
J Pharmacol Exp Ther; 2004 Dec; 311(3):904-12. PubMed ID: 15277581
[TBL] [Abstract][Full Text] [Related]
18. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Okumura T; Murata Y; Hizue M; Matsuura T; Naganeo R; Kanai Y; Murase A; Sakakibara A; Fujita I; Nakao K
Eur J Pharmacol; 2006 Jun; 539(1-2):125-30. PubMed ID: 16690052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
